Evidence map›Paper›PMID 42360520›Full record

ArticleBreast cancer research and treatment2026

Comments on: Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy.

Rajesh Prasad Jayaswal, Shailendra Thapliyal, Rama Kumari Badyal

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rajesh Prasad JayaswalDepartment of Medical Laboratory Sciences, University Institute of Allied Health Sciences, Chandigarh University, Mohali, Punjab, 140413, India. rpjayaswal.jec@gmail.com.ORCID http://orcid.org/0000-0001-7158-5630
Shailendra ThapliyalUttaranchal Institute of Technology, Uttaranchal University, Dehradun, Uttarakhand, 248007, India.ORCID http://orcid.org/0009-0002-6212-2057
Rama Kumari BadyalDepartment of Pathology, Govt. Medical College/Rajindra Hospital, Patiala, Punjab, 147001, India.ORCID http://orcid.org/0000-0002-7715-664X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This correspondence comments on LeVee et al.'s real-world study of neoadjuvant chemo-immunotherapy in early-stage triple-negative breast cancer. We highlight diabetes as a potentially modifiable host-state factor influencing pathologic complete response and propose a metabolic immunotherapy-readiness framework integrating glycaemic control, treatment delivery, endocrine monitoring, and equity-focused implementation. This perspective aims to support globally applicable strategies for improving chemo-immunotherapy effectiveness and access.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImmunotherapyTriple Negative Breast NeoplasmsFemaleHumansNeoadjuvant TherapyNeoplasm StagingPathologic Complete ResponseTreatment OutcomeDiabetesMetabolic immunotherapy readinessNeoadjuvant chemo-immunotherapyPathologic complete responsePembrolizumabTriple-negative breast cancer

Identifiers

PMID42360520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.